News
Sutro Biopharma Presented on Advances in Novel Immunostimulatory Antibody-Drug Conjugate Modality at the 12th Annual World ADC
SOUTH SAN FRANCISCO, Calif., March 30, 2022– Sutro Biopharma, Inc. (“Sutro” or the “Company”) (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create...
12th Annual World ADC London 2022 – Presentations
World ADC 2022 presentation titled, “A New Molecular Class to target Tumor Immunity by both disrupting the tumor and enabling the immune system” presented by Trevor Hallam, Ph.D., President of Scientific and Chief Scientific Officer.World ADC 2022 presentation...
Cowen 42nd Annual Healthcare Conference – Presentation
Sutro Biopharma to Participate in the Cowen 42nd Annual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., March 3, 2022– Sutro Biopharma, Inc. (“Sutro” or the “Company”) (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create...
Sutro Biopharma Reports Full Year 2021 Financial Results, Business Highlights, and Anticipated 2022 Milestones
- Promising STRO-002 initial data on Phase 1 dose-expansion cohort were reported in January 2022, providing initial insights on a go-forward dosing regimen and biomarker enrichment strategy - - Cash, cash equivalents and marketable securities totaled $229.5 million as...
63rd American Society of Hematology (ASH) Annual Meeting and Exposition – Non-Audio Presentation
40th Annual J.P. Morgan Heathcare Conference – Presentation
Webcast, Jan 13, 2022 at 11:15AM EST
Sutro Biopharma to Present at the 40th Annual J.P. Morgan Virtual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 6, 2022– Sutro Biopharma, Inc. (“Sutro” or the “Company”) (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create...
Virtual KOL Event: Discussion of STRO-002 Interim Dose Expansion Cohort Data – Presentation
Webcast, Jan 5, 2022 at 5:00pm EST
Sutro Biopharma Announces Interim Data from Dose-Expansion Cohort of STRO-002 Phase 1 Study for Patients with Advanced Ovarian Cancer
- 33% Objective Response Rate (ORR) was observed in 33 RECIST evaluable patients across all FolRα expression levels and both dose levels. - Dose response was observed, with a 47% ORR in 17 patients who started at the 5.2 mg/kg dose level. - Tumor proportion score...